1. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2022)
https://pubmed.ncbi.nlm.nih.gov/35908570/

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. (2022)
https://pubmed.ncbi.nlm.nih.gov/35896281/

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. (2022)
https://pubmed.ncbi.nlm.nih.gov/35853675/

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. (2022)
https://pubmed.ncbi.nlm.nih.gov/35853675/

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. (2022)
https://pubmed.ncbi.nlm.nih.gov/36064592/

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial. (2022)
https://pubmed.ncbi.nlm.nih.gov/35863864/